Farbovil

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Farbovil

Property Description
Active Ingredient Ketoprofen
Pharmacological Class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common Use Relief of pain, inflammation, and fever
Origin Synthetic propionic acid derivative
Dosage Forms Capsule, tablet, gel, injectable solution

Farbovil is a pharmaceutical preparation containing the active ingredient ketoprofen, which is universally classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). This synthetic agent belongs to the propionic acid derivative class, a grouping known for its established triple pharmacological capacity: functioning as an analgesic (pain reducer), an anti-inflammatory agent, and an antipyretic (fever reducer). Ketoprofen is clinically recognized for its rapid onset of action and is often utilized for managing acute episodes of discomfort requiring prompt symptomatic relief.

The compound is prepared as a single-ingredient product, focusing the therapeutic action solely on ketoprofen, which is typically synthesized as a racemic mixture. The availability of Farbovil in diverse dosage forms—including immediate-release capsules and slower-acting extended-release tablets—distinguishes it from products offered in only one format, providing versatility for short-term or continuous management needs. Other forms include a topical gel for localized relief and an injectable solution for parenteral administration.

The general therapeutic purpose of Farbovil is to manage discomfort and inflammatory symptoms by interrupting the molecular pathways that generate them. It achieves this by inhibiting cyclooxygenase (COX) enzymes, thereby reducing the synthesis of prostaglandins, the primary chemical signals for pain, fever, and inflammation. This mechanism provides comprehensive symptomatic relief, targeting the discomfort at its molecular source.

Regulatory References

  1. Ketoprofen - LiverTox - NIH

What side effects are possible with Farbovil?

Possible side effects and safety information

Farbovil, which contains ketoprofen, an NSAID, has an officially documented safety profile structured around potential adverse reactions and specific constraints as outlined in government regulatory documents.

Serious Adverse Reactions

Official labeling highlights the risk of serious cardiovascular thrombotic events, including Myocardial Infarction and Stroke. Additionally, there is a documented risk of serious gastrointestinal events, such as bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. Severe dermatological reactions (e.g., Stevens-Johnson Syndrome) and anaphylactic reactions are also documented.

Frequency and Organ Systems

Adverse reactions are classified by frequency, ranging from Common (e.g., dyspepsia, nausea, abdominal pain) to Rare (e.g., peptic ulcer, photosensitisation). These effects are grouped by System-Organ Class (SOC) to map their impact on the body, involving the Gastrointestinal, Renal and Urinary, Cardiac and Vascular, Nervous System, and Skin domains.

Safety Considerations and Constraints

Official documents note that risk may increase with the duration of use, and serious cardiovascular events may begin early in the course of treatment. Older patients are noted to be at a greater risk for serious gastrointestinal events. Farbovil is contraindicated for the treatment of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery and during the third trimester of pregnancy due to risks to the fetus. Close monitoring of renal and hepatic function is required during long-term therapy.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Farbovil (ketoprofen) is officially documented to present with systemic manifestations, primarily involving gastrointestinal distress such as nausea, vomiting, epigastric pain, and diarrhea. Regulator-listed central nervous system (CNS) effects include drowsiness, lethargy, confusion, and dizziness.

Severe Outcomes and Immediate Action The official profile documents rare but serious outcomes such as gastrointestinal bleeding, acute renal failure, and severe neurological effects like seizures and coma. Cardiovascular effects, including hypotension or hypertension, are also observed in overdose situations. Large overdoses are documented to cause serious damage in both children and adults.

Due to the risk of these severe complications, government regulatory sources explicitly mandate that medical help must be sought right away for any suspected overdose. Immediate action requires contacting the national toll-free Poison Control Center helpline or local emergency services.

Management Protocol The official labeling states that no specific antidote is known for this overdose. Management is therefore strictly symptomatic and supportive. Officially described procedural steps may include gastric lavage to empty the stomach and the administration of activated charcoal. Hospital monitoring of vital signs and specialized diagnostic tests are required during emergency management.

Therapeutic Uses of Farbovil

Quick Facts: Farbovil

  • Therapeutic Domain: Used to address certain symptoms associated with chronic inflammatory conditions.
  • Primary Benefit: Works to help reduce the occurrence of disease flare-ups.
  • Role in Therapy: May be considered as part of a comprehensive management strategy.

What Farbovil Treats: Main Uses and Benefits

Farbovil is a treatment option utilized in the management of specified chronic inflammatory diseases. It is not intended as a cure but is prescribed to address the underlying processes that contribute to symptom burden.

The primary function of Farbovil is to work to help reduce the frequency and severity of certain disease manifestations. Clinical experience suggests that, in some individuals, the medication may assist in maintaining a state of reduced disease activity. This can contribute to an improved ability to manage daily living activities related to the condition.

When incorporated into a broader care plan, Farbovil may help support long-term disease management objectives. Before initiating any treatment, individuals should review the potential effects and necessary monitoring with their prescribing healthcare professional.

Eligibility and Restrictions for Use

Who Can and Cannot Use Farbovil?

Eligibility for Farbovil (ketoprofen, an NSAID) is strictly determined by regulatory labeling, which mandates specific exclusions and conditional use categories.

Contraindicated Populations (Must Not Use)

Farbovil is contraindicated and must not be used in patients with:

  • A known allergy or hypersensitivity to ketoprofen, aspirin, or any other NSAID.
  • A history of active peptic ulcer or recurrent gastrointestinal bleeding.
  • Severe uncontrolled heart failure or advanced renal disease.
  • Perioperative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.
  • Pregnancy at 30 weeks gestation and later (third trimester).

Age and Physiological Restrictions

Population Group Eligibility Status (Regulatory Wording)
Pediatric Patients (Under 18) Not recommended; safety and effectiveness have not been established in this population.
Older Adults (Geriatric) Use is permitted but requires close monitoring due to increased risk of toxicity.
Lactating Mothers Not recommended as the drug is known to be excreted in human milk.

Conditional Use and Monitoring

Patients with impaired renal function or chronic liver disease require close monitoring and may necessitate dosage reduction as dictated by official prescribing information. Use is also restricted in pregnant women between 20 and 29 weeks gestation, requiring the lowest dose for the shortest duration.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes documented interaction patterns as stated in official government regulatory documents.

Category Official Interaction Statements
Contraindicated Combinations Use is formally prohibited in the setting of CABG surgery and for patients with NSAID-sensitive asthma. Co-administration with other NSAIDs (including COX-2 inhibitors) should be avoided.
Pharmacodynamic Risk Concomitant use with Anticoagulants (e.g., Warfarin), Antiplatelet agents, Corticosteroids, or SSRIs/SNRIs significantly increases the documented risk of gastrointestinal ulceration and/or bleeding.
Exposure Modification The drug may cause an increase in the plasma concentration of Lithium and Methotrexate due to reduced renal elimination, raising concerns for toxicity. Concurrent use with Cyclosporine or Tacrolimus also increases the risk of nephrotoxicity.
Efficacy & Renal Risk Concurrent use with Diuretics or ACE Inhibitors/ARBs can result in a reduced effectiveness of these antihypertensive agents and an increased risk of renal impairment.
Food & Substance Constraints Alcohol co-administration increases the risk of stomach bleeding. For the extended-release form, a high-fat meal delays the time to maximum concentration (Tmax) by approximately two hours.

Population-Specific Notes: Older adult patients have a greater risk for interaction-related gastrointestinal events and renal impairment when co-administered with diuretics or RAAS agents. Chronic liver disease alters the drug's pharmacokinetics, potentially leading to higher blood levels. The regulatory documentation also notes the drug does not induce drug-metabolizing enzymes.

Mechanism of Action

Farbovil is the (S)-(+)-enantiomer, dexketoprofen, of the non-steroidal compound ketoprofen. It functions as a non-selective inhibitor of cyclooxygenase (COX) isoenzymes, specifically targeting Prostaglandin G/H synthase 1 (COX-1) and Prostaglandin G/H synthase 2 (COX-2).

This interaction involves competitive inhibition at the active site, blocking the conversion of arachidonic acid into prostaglandin endoperoxides, which are precursors to eicosanoids such as Prostaglandin E2 (PGE2) and Thromboxane B2 (TxB2). The intracellular consequence is a dose-dependent reduction in the synthesis and local concentration of these lipid mediators, particularly at sites of tissue distress.

System-level physiological modulation occurs through the generalized decrease in PGE2 production, which affects multiple downstream signaling cascades. Specifically, the reduced PGE2 concentration modulates peripheral and central sensitization of nociceptive neurons, and it decreases local vascular permeability and inflammatory cell recruitment.

Dosage and Administration Information

How to Use Farbovil: Official Administration Guidelines

Farbovil (ketoprofen) is administered according to a structured protocol detailed in official regulatory documents, focusing on the approved routes, frequency, and maximum allowable doses. The medicine is available in various official forms, including immediate-release (IR) and extended-release (ER) capsules or tablets for oral intake, a topical gel, and an injectable solution for parenteral administration.

Standardized Dosing and Frequency

For most systemic uses, the general principle is to use the lowest effective dose for the shortest duration necessary. The dosing schedule differs based on the formulation:

Formulation Typical Adult Schedule Maximum Daily Dose
Immediate-Release (Oral) Divided doses (e.g., three or four times daily) 300 mg
Extended-Release (Oral) Once daily (QD) 200 mg

Administration Conditions and Adjustments

Oral administration is typically done with a full glass of water, and taking the dose with food, milk, or an antacid may be advised to minimize potential stomach upset.

Regulatory instructions require specific procedural adherence for certain forms: extended-release capsules must be swallowed whole and must not be crushed, chewed, or opened to ensure proper release of the active ingredient. Furthermore, for specific populations, mandatory dose modifications are required. Initial doses for older adults (geriatric) and patients with impaired renal or hepatic function must be reduced from the standard adult range. If a scheduled dose is missed, official guidance is to skip that dose and resume the regular schedule, with an explicit instruction not to take a double dose to compensate.

Recent Clinical Evidence

Research evidence / Overview of studies for Farbovil

The evidence base for Farbovil, which contains the active ingredient ketoprofen, primarily consists of Randomized Controlled Trials (RCTs) and meta-analyses that explore its use in two main areas: chronic inflammatory joint conditions and various sources of acute pain. Research focuses on monitoring changes in patient-reported symptoms and functional ability over defined time intervals.


Evidence for use in Chronic Inflammatory Conditions

Research examined Farbovil in contexts involving conditions characterized by fluctuating or episodic manifestations, such as osteoarthritis and rheumatoid arthritis. These chronic joint conditions are often marked by functional limitations and periods of heightened symptom activity.

What researchers studied

Short-term and intermediate-term RCTs have been applied in studies examining patient-reported experiences in adults with these conditions. These trials primarily monitored patient-reported outcomes describing perceived discomfort, including outcomes related to physical discomfort (pain intensity scales), the duration of morning stiffness, and outcomes reflecting daily functioning or activity level.

What the studies reported (neutral summary)

Studies monitored symptom reports in the observed populations over follow-up periods ranging from a few weeks up to three months. Findings describe measured patterns observed in the studies related to changes in pain scores and self-assessed mobility. Evidence from these studies contributes to understanding symptom patterns in conditions where symptoms may vary in intensity.


Evidence for use in Acute Pain and Inflammation

This part will focus on the research base exploring short-term symptom patterns, including data from single-dose and short-course trials in contexts like postoperative pain and soft tissue injury, outlining the time-based and intensity-based outcomes that were evaluated.

What researchers studied

The core research includes single-dose and short-course RCTs conducted during periods of increased symptom activity. Studies primarily examined outcomes describing episodic or acute changes, such as the time it takes for relief to be noted and the total amount of pain experienced over the first few hours after taking the medicine. Study populations involved adults experiencing moderate to severe acute pain.

What the studies reported (neutral summary)

Findings describe patterns observed in the studies where measured pain scores followed a pattern when compared to inactive controls over the initial short observation intervals. Research examined short-term changes in pain intensity. The data show patterns related to the proportion of patients who achieved a predefined reduction in pain within the hours immediately following a single dose. The evidence regarding outcomes in pain related to specific conditions, such as vaso-occlusive crisis, was reported as not significant for primary endpoints in one trial.


Long-Term Studies and Follow-Up

Long-term follow-up data for Farbovil, as with many NSAIDs, are more focused on extended use in chronic conditions. Research has monitored measured outcomes over defined time intervals in groups of patients with chronic arthritis conditions, with some prospective studies including observation periods longer than three months. However, long-term outcomes are not fully established. The existing studies provide limited information for long-term outcomes related to functional status and activity levels after many months or years of continuous use.


What is Still Uncertain About Farbovil Research

A primary limitation is that the follow-up durations were limited in many of the key trials, meaning long-term outcomes related to functional status are not fully established. Furthermore, evidence quality varies across studies, particularly when comparing different formulations or examining comparisons against every possible alternative medicine. The data for certain groups are noted as limited, particularly for long-term data and measured outcomes in very young children or patients with complex, co-occurring health issues.

Key Studies & References NIH LiverTox: Ketoprofen (Information on metabolism, use, and associated risks)

Frequently Asked Questions (FAQ)

Common questions about Farbovil (FAQ)


Q: What is the main reason doctors prescribe Farbovil?

Official regulatory documents indicate that Farbovil (ketoprofen) is approved for the management of the signs and symptoms of chronic inflammatory conditions, such as rheumatoid arthritis and osteoarthritis. It is also indicated for the temporary relief of mild to moderate pain and discomfort associated with primary dysmenorrhea (menstrual cramps).


Q: Is Farbovil the same kind of drug as [common drug name]?

Farbovil (ketoprofen) is officially classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). This places it in the same class of medicines as other commonly known pain and inflammation relievers. It functions as a propionic acid derivative, which is a specific chemical group within the NSAID class.


Q: What's the difference between Farbovil and a supplement?

Farbovil is a prescription pharmaceutical drug containing the synthetic active ingredient ketoprofen. Unlike dietary supplements, the approval of a drug requires governmental bodies (like the FDA or EMA) to review specific clinical evidence establishing its efficacy and safety for approved uses.


Q: How quickly should someone expect to notice the effects of Farbovil?

Official research focuses on the time it takes for a change in reported pain to be noted. According to official product information, ketoprofen is described as having a relatively rapid onset of action for the purpose of symptomatic pain relief. The precise timing of effects is subject to individual physiological factors and the specific formulation used.


Q: How long does a dose of Farbovil typically stay in your system?

Pharmacokinetic data published in official documents indicates that ketoprofen has a short plasma elimination half-life, generally noted to be between one to three hours. This half-life describes the time it takes for the concentration of the medicine in the blood to decrease by half.


Q: Do people take Farbovil long-term or just for a short time?

Official guidance permits the use of Farbovil for the short-term treatment of acute pain or the longer-term management of chronic conditions like arthritis. Official warnings consistently include the general principle of aiming for the lowest effective dose used for the shortest duration needed.


Q: Is it okay to stop taking Farbovil suddenly?

Official regulatory records state that Farbovil (ketoprofen) is not classified as a controlled substance and is not considered habit-forming. However, the decision to stop using this or any medication should always be discussed with a healthcare professional before making any changes.


Q: Does Farbovil cause weight gain or weight loss?

Regulatory documents listing reported adverse reactions include both weight gain and weight loss as documented events reported in post-marketing surveillance or clinical trial data. These events are listed among the documented occurrences reported in clinical trial or post-marketing data.


Q: Is Farbovil a controlled substance or habit-forming?

Farbovil (ketoprofen) is not classified as a controlled substance by US regulatory bodies (e.g., the DEA) and is not noted as having a potential for abuse or dependence in official drug labeling.


Q: Can people with kidney problems use Farbovil?

Farbovil is contraindicated (must not be used) in patients with advanced renal (kidney) disease. For patients with kidney function impairment that is not advanced, official documents indicate that close medical monitoring and possible dosage adjustments are necessary.


Q: Is there any official information about Farbovil use while breastfeeding?

Official regulatory information states that ketoprofen is known to be excreted in human milk. Due to the potential for adverse reactions in breastfed infants, the use of ketoprofen during lactation is a matter that requires careful consideration by a healthcare professional.


Q: What should I do if I think Farbovil isn't working for me?

Official principles of use state that the lowest effective dose should be used. Official documents suggest that if desired symptomatic effects are not being achieved, a re-evaluation of the current treatment plan and diagnosis is warranted.


Q: Does taking Farbovil affect my ability to drive or operate machinery?

Official labeling warns that adverse effects such as dizziness, drowsiness (feeling sleepy), and vertigo (spinning sensation) have been reported with the use of this medicine. Regulatory documents include a warning noting that patients must consider these potential effects related to driving or operating complex machinery.


Q: Is Farbovil expensive, and is there a generic version available?

Since the active ingredient ketoprofen has been available for many years, various regulatory bodies have approved generic versions and equivalent formulations for marketing in different jurisdictions. Official records show that generic versions and equivalent formulations have been approved for marketing in various jurisdictions.


Q: Are there different strengths or forms of Farbovil available?

Yes, official documentation describes Farbovil (ketoprofen) as being available in multiple official forms, including immediate-release and extended-release oral capsules/tablets, as well as a topical gel and an injectable solution. Each form is available in a range of approved dosage strengths.


Q: Is Farbovil known to cause or worsen anxiety?

Official labeling reports side effects related to the nervous system and psychiatric function. Adverse reactions such as nervousness, confusion, and insomnia (difficulty sleeping) have been documented in official clinical trial and post-marketing data for ketoprofen.


Q: Does Farbovil affect sleep patterns?

Official documents list changes in sleep patterns as documented adverse reactions related to the use of Farbovil (ketoprofen). These include reports of insomnia (difficulty falling or staying asleep), as well as drowsiness and vivid dreams.


Q: Is it possible to be allergic to the inactive ingredients in Farbovil?

Official documentation for this drug specifies that the product is contraindicated (must not be used) in patients with a known hypersensitivity or allergy not only to the active ingredient but also to any of the excipients (inactive ingredients) used in the formulation.


Q: What is the typical timeframe before a doctor might change treatment if Farbovil isn't effective?

Official regulatory guidance for chronic conditions suggests that the initial therapeutic response may be monitored over a period of several days or weeks. The period allows for a medical professional to evaluate the need for treatment adjustment or alternative therapy.


Q: Is Farbovil related to or derived from any natural substances?

Official regulatory documents clearly describe Farbovil (ketoprofen) as a synthetic compound. It belongs to the propionic acid derivative class, meaning it is not derived from natural substances.


Q: Can Farbovil affect my blood pressure?

Official warnings state that NSAIDs, including Farbovil, can lead to the onset of new high blood pressure (hypertension) or the worsening of pre-existing high blood pressure. Regulatory documents include a requirement that blood pressure should be monitored closely during treatment.


Q: What does 'clinical evidence' mean when talking about Farbovil?

'Clinical evidence,' in the context of drug approval, refers to the scientific data, primarily generated from Randomized Controlled Trials (RCTs) and systematic reviews. This information is what regulatory bodies use to establish the drug's approved uses, appropriate dosing, and documented safety profile.


Q: If I feel better, can I just stop taking Farbovil?

Official principles of use state that the shortest duration necessary should be used. Cessation of any medication is a decision that falls under professional medical guidance, even when symptoms improve.

How should Farbovil be stored and disposed of?

Storage & Disposal Scope

Labeled Storage Temperature Requirements Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Light/Moisture Protection Requirements Protect from moisture and away from direct light.
Stability after Opening/Reconstitution For multi-dose injectable solution, use contents within 4 months of first vial puncture.
Handling Requirements Keep from freezing and away from excess heat.
Packaging-Related Storage Rules Keep the medicine in the container it came in, and keep the container tightly closed with a child-resistant closure.
Disposal Instructions Dispose of unused or expired product using a drug take-back program or an authorized collection site.
Environmental or Controlled-Waste Disposal Requirements Do not flush this medicine or pour it down a sink or drain, unless specifically instructed by the labeling.
Child-Protection Storage Requirements Keep this and all drugs out of the sight and reach of children.

Storage/Disposal Classifications (High-Level)

Storage Condition Type Controlled Room Temperature / Protection from Light and Moisture
In-Use Stability Classification 4 months after first puncture for multi-dose liquid forms
Regulatory Basis FDA, NIH/MedlinePlus, EMA/SmPC Guidelines
Storage-Context Constraints Do not freeze; store in original, tightly closed, child-resistant container.

Resulting Storage & Disposal Structure

Official regulatory documents define how the product must be stored by mandating a specific temperature range and protection from environmental factors (moisture, light, freezing) to ensure its stability. Packaging rules reinforce product integrity and mandate child-resistant closures and protection from children's access. Disposal instructions direct the user toward formal waste collection methods like take-back programs, or controlled household trash disposal, with an explicit rule against disposal in wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Farbovil found in:

A-Z Index: